QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.107.129171v1 324/1/224    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Alier, K. A. Articles by Smith, P. A. Search for Related Content PubMed PubMed Citation Articles by Alier, K. A. Articles by Smith, P. A.

NEUROPHARMACOLOGY

Intrathecal Administration of Proteinase-Activated Receptor-2 Agonists Produces Hyperalgesia by Exciting the Cell Bodies of Primary Sensory Neurons

Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada (K.A.A., J.A.E., P.L.S., P.A.S.); Department of Pharmacology and Therapeutics, University of Calgary, Calgary, Alberta, Canada (N.C., L.C., K.C., N.V.); and Johnson & Johnson Pharmaceutical Research and Development, Spring House, Pennsylvania (P.A.-G.)

Proteinase-activated receptors (PARs) are a family of G-protein-coupled receptors that are activated by endogenous serine proteinases that cleave the N-terminal domain of the receptor unmasking a "tethered ligand" sequence. Trypsin and other agonists at PAR₂ act on peripheral nerves to augment the transfer of nociceptive information. We tested whether PAR₂ agonists also exert a spinal pronociceptive effect by i.t. administering the selective ligand, Ser-Leu-Ile-Gly-Arg-Leu-NH₂ (SLI-GRL). This produced thermal and mechanical hyperalgesia in rats and mice and augmented mechanical and thermal hyperalgesia seen in the formalin inflammatory pain test. Effects of SLIGRL were abrogated in PAR₂-deficient mice and were not seen with the inactive control peptide, Leu-Arg-Gly-Ile-Leu-Ser-NH₂. Surprisingly, electrophysiological studies, using whole-cell recording from rat substantia gelatinosa neurons, failed to demonstrate an increase in excitatory transmission or neuronal excitability following treatment with SLIGRL or trypsin. In fact, the actions of trypsin were consistent with a decrease in dorsal horn excitability. SLIGRL and trypsin did, however, depolarize and increase the excitability of large, medium and small primary afferent, dorsal root ganglion neurons. The effects were associated with an increase in conductance at hyperpolarized potentials and a decrease in conductance at depolarized potentials. PAR₂-like immunoreactivity was found in DRG but not in spinal dorsal horn. These results suggest that activation of DRG neuron cell bodies may account for the pronociceptive actions of i.t. applied PAR₂ agonists. They also imply that pathophysiological release of PAR₂-activating proteases in the vicinity of DRG neurons may produce profound effects on nociceptive processing in vivo.

Address correspondence to: Dr. Peter Smith, Department of Pharmacology, University of Alberta, 9.75 Medical Sciences Building, Edmonton, AB T6G 2H7, Canada. E-mail: peter.a.smith{at}ualberta.ca